Fennec Pharmaceuticals Inc. (FENC) Stock Price & Growth Analysis - Tweevest

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Fennec Pharmaceuticals Inc.

FENC

NASDAQ

Unprofitable

Unprofitable

152M

Biotechnology

Next Earning date - 20 Mar 2025

152M

Biotechnology

Next Earning date - 20 Mar 2025

5.54USD

-0.09 ( -1.60%)

Relative Strenght

41

Volume Buzz

-70%

Earning Acce

No

Dist 52w H.

52%

Quote Panel

Updated January 20, 2025

1W -1.77 % 1M -10.79 % 3M 18.88 % 1Y -45.95 %

Key Metrics

Market Cap
151.95M
Shares Outstanding
27.43M
Share in Float
22.90M
Dividende
0

Earning Date
20 Mar 2025
Price Target
5.54
Average Volume
120575
Beta
0.267

Range
3.96-11.49
Industry
Biotechnology
Website
https://www.fennecpharma.com
Sector
Healthcare

Fundamentals

Relative Strength

FENC

Sector

loading...

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$48M

591%

2025-Revenue

$0.03

84%

2025-EPS

$6M

-20%

2025-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

0.00(-100.00%)

Number of analyst

0

Last analyst upgrade/downgrade

Cantor Fitzgerald

upgrade

Previous: Not converted

2022-11-22

Now: Overweight

JonesTrading

initialise

Previous: Not converted

2022-09-07

Now: Buy

Oppenheimer

initialise

Previous: Not converted

2022-09-07

Now: Outperform

Morgan Stanley

initialise

Previous: Not converted

2022-09-07

Now: Equal-Weight

Earnings Growth

YoY

Current

Estimates

Q4.22

N/A

-0.26
vs -0.18

Q1.23

N/A

-0.23
vs -0.14

Q2.23

N/A

-0.21
vs -0.19

Q3.23

N/A

-0.07
vs -0.31

Q4.23

N/A

-0.10
vs -0.26

Q1.24

+304%

0.47
vs -0.23

Q2.24

N/A

-0.20
vs -0.21

Q3.24

N/A

-0.21
vs -0.07

Q4.24

N/A

-0.13
vs -0.10

Q1.25

N/A

-0.12
vs 0.47

Sales Growth

YoY

Current

Estimates

Q4.22

NA

1.5M vs NA

Q1.23

NA

1.7M vs NA

Q2.23

NA

3.3M vs NA

Q3.23

NA

6.5M vs NA

Q4.23

+552%

10M vs 1.5M

Q1.24

+1406%

25.3M vs 1.7M

Q2.24

+118%

7.3M vs 3.3M

Q3.24

+7%

7M vs 6.5M

Q4.24

-21%

7.9M vs 10M

Q1.25

-67%

8.4M vs 25.3M

Return on Equity

QoQ

Q4.22

+303%

3.03
vs -2.91

Q1.23

+104%

1.04
vs 3.03

Q2.23

+56%

0.56
vs 1.04

Q3.23

+18%

0.18
vs 0.56

Q4.23

+24%

0.24
vs 0.18

Q1.24

+426%

4.26
vs 0.24

Q2.24

+409%

4.09
vs 4.26

Q3.24

+111%

1.11
vs 4.09

Institutionnal Ownership

QoQ

Q4.22

47

47
vs 42

12%

Q1.23

58

58
vs 47

23%

Q2.23

60

60
vs 58

3%

Q3.23

59

59
vs 60

-2%

Q4.23

58

58
vs 59

-2%

Q1.24

67

67
vs 58

16%

Q2.24

62

62
vs 67

-7%

Q3.24

62

62
vs 62

NA

Earnings Growth

Latest News

FENC

globenewswire.com

6 hours ago

Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales

FENC

globenewswire.com

6 hours ago

Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management

FENC

globenewswire.com

6 hours ago

Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

FENC

globenewswire.com

7 hours ago

Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

FENC

zacks.com

8 hours ago

Adherex Technologies Inc. (FENC) Reports Q3 Loss, Misses Revenue Estimates

FENC

seekingalpha.com

22 hours ago

Fennec Pharmaceuticals Inc. (FENC) Q3 2024 Earnings Call Transcript

New Feature Coming Soon, Stay Tuned!

Shape

Shape